Roche to pay $250M for Good Therapeutics and its targeted drug technology Biopharmadive Sep 7, 2022 Media
Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program MedCityNews Sep 7, 2022 Media
Roche to acquire Good Therapeutics’ lead drug program for $250M, plus milestone payments GeekWire Sep 7, 2022 Media
Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy STAT Sep 7, 2022 Media
Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin Endpoints News Sep 7, 2022 Media
Roche snaps up PD-1-focused Good Therapeutics for $250M; ‘Sky’s the limit’ for spinout Fierce Biotech Sep 7, 2022 Media